Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal

Addiction

Volumn 101, Issue 11, 2006, Pages 1614-1621

  Ramaekers, J G ^a   Kuypers, K P C ^a   Samyn, N ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b National Institute of Criminalistics and Criminology   (Belgium)

Author keywords

MDMA; Methylphenidate; On the road driving; Stimulants

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; PLACEBO; RECREATIONAL DRUG;

ACCURACY; ADAPTATION; ADULT; ARTICLE; BODY POSITION; CAR DRIVING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECELERATION; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INTOXICATION; DRUG METABOLISM; DRUG WITHDRAWAL; EUROPE; FEMALE; HUMAN; MALE; RESPONSE TIME; VELOCITY;

ADULT; AMPHETAMINE-RELATED DISORDERS; AUTOMOBILE DRIVING; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HALLUCINOGENS; HUMANS; MALE; METHYLPHENIDATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 33749530256     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01566.x     Document Type: Article

References (44)

1. Morgan M. J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000; 152: 230-48.
2. Parrott A. C. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16: 557-77.
3. Reneman L., Booij J., Majoie C. B., Van Den Brink W., Den Heeten G. J. Investigating the potential neurotoxicity of ecstasy (MDMA): an imaging approach. Hum Psychopharmacol 2001; 16: 579-88.
4. Cole J. C., Sumnall H. R. Altered states: the clinical effects of ecstasy. Pharmacol Ther 2003; 98: 35-58.
5. Logan B. K., Couper F. J. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci 2001; 46: 1426-33.
6. Riley S. C., James C., Gregory D., Dingle H., Cadger M. Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001; 96: 1035-47.
7. Akram G., Forsyth A. J. Speed freaks? A literature review detailing the nature and prevalence of dance drugs and driving. Int J Drug Policy 2000; 11: 265-77.
8. Logan B. K., Couper F. J. 3,4-Methylenedioxymethamphetamine - effects on human performance and behavior. Forensic Sci Rev 2003; 15: 12-28.
9. Schifano F. Dangerous driving and MDMA. J Serotonin Res 1995; 1: 53.
10. Lamers C. T., Ramaekers J. G., Muntjewerff N. D. et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 2003; 17: 379-87.
11. Brookhuis K. A., De Waard D., Samyn N. Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology (Berl) 2004; 173: 440-5.
12. Curran H. V., Travill R. A. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction, 1997; 92: 821-31.
13. Parrott A. C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl) 1998; 139: 261-8.
14. O'Hanlon J. F., Haak T. W., Blaauw G. J., Riemersma J. B. Diazepam impairs lateral position control in highway driving. Science 1982; 217: 79-81.
15. Brookhuis K. A., de Waard D. The use of psychophysiology to assess driver status. Ergonomics 1993; 36: 1099-110.
16. Ramaekers J. G., O'Hanlon J. F. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47: 261-6.
17. Ramaekers J. G., Lamers J., Verhey F., Muntjewerff N., Mobbs E., Sanders N. et al. A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology (Berl) 2002; 159: 203-10.
18. Federici M., Geracitano R., Bernardi G., Mercuri N. B. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol Psychiatry 2005; 57: 361-5.
19. Boutrel B., Koob G. F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004; 27: 1181-94.
20. Scahill L., Carroll D., Burke K. Methylphenidate: mechanism of action and clinical update. J Child Adolesc Psychiatr Nurs 2004; 17: 85-6.
21. Green A. R., O'Shea E., Colado M. I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004; 500: 3-13.
22. Mackworth J. F. The effect of amphetamine on the detectability of signals in a vigilance task. Can J Psychol 1965; 19: 104-10.
23. Rapoport J. L., Buchsbaum M. S., Weingartner H., Zahn T. P., Ludlow C., Mikkelsen E. J. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980; 37: 933-43.
24. Koelega H. S. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl) 1993; 111: 1-16.
25. Mills K. C., Spruill S. E., Kanne R. W., Parkman K. M., Zhang Y. The influence of stimulants, sedatives, and fatigue on tunnel vision: risk factors for driving and piloting. Hum Factors 2001; 43: 310-27.
26. De Wit H., Enggasser J. L., Richards J. B. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 2002; 27: 813-25.
27. Wesensten N. J., Killgore W. D., Balkin T. J. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005; 14: 255-66.
28. Mehta M. A., Owen A. M., Sahakian B. J., Mavaddat N., Pickard J. D., Robbins T. W. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20: RC65.
29. Arnsten A. F., Dudley A. G. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005; 1: 2.
30. Caldwell J. A., Caldwell J. L., Darlington K. K. Utility of dextroamphetamine for attenuating the impact of sleep deprivation in pilots. Aviat Space Environ Med 2003; 74: 1125-34.
31. Kenagy D. N., Bird C. T., Webber C. M., Fischer J. R. Dextroamphetamine use during B-2 combat missions. Aviat Space Environ Med 2004; 75: 381-6.
32. Couper F. J., Pemberton M., Jarvis A., Hughes M., Logan B. K. Prevalence of drug use in commercial tractor-trailer drivers. J Forensic Sci 2002; 47: 562-7.
33. Jerome L. ADHD and driving safety. Can Med Assoc J 2003; 169: 16.
34. Jerome L., Segal A. Benefit of long-term stimulants on driving in adults with ADHD. J Nerv Ment Dis 2001; 189: 63-4.
35. Kuypers K. P., Ramaekers J. G. Transient memory impairment after acute dose of 75 mg 3.4-methylenedioxymethamphetamine. J Psychopharmacol 2005; 19: 633-9.
36. Kuypers K. P. C., Ramaekers J. G. Acute dose of MDMA (75mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology in press.
37. Augsburger M., Donze N., Menetrey A., Brossard C., Sporkert F., Giroud C. et al. 2005 Concentration of drugs in blood of suspected impaired drivers. Forensic Sci Int 2005; 153: 11-15.
38. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R. et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830-3.
39. Volkow N. D., Wang G. J., Fowler J. S. Imaging studies of cocaine in the human brain and studies of the cocaine addict. Ann NY Acad Sci 1997; 820: 41-54;discussion 54-5.
40. Fillmore M. T., Kelly T. H., Martin C. A. Effects of d-amphetamine in human models of information processing and inhibitory control. Drug Alcohol Depend 2005; 77: 151-9.
41. Deller T., Sarter M. Effects of repeated administration of amphetamine on behavioral vigilance: evidence for 'sensitized' attentional impairments. Psychopharmacology (Berl) 1998; 137: 410-4.
42. Morgan M. J. Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998; 19: 252-64.
43. Butler G. K., Montgomery A. M. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alcohol Depend 2004; 76: 55-62.
44. Ramaekers J. G., Kuypers K. P. Acute effects of 3,4- methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuropsychopharmacology 2006; 31: 1048-55.